CBIO

Crescent Biopharma Inc. (CBIO) | Rumor.io

Crescent Biopharma

CBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,188

Bullish sentiment (50-day avg)100%

Price to earnings ratio2.58

Market capitalization539.7M

Earnings per share-0.14

Dividend yield (TTM)663.9%

Revenue (annual)10.8M

Net income (annual)-153.9M

Social

What share of all stock conversation is about CBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 30

Crescent Biopharma, Inc. ($CBIO) is a clinical-stage biotech company developing next-gen oncology treatments, including a PD-1/VEGF bispecific.
The company's stock has shown confidence-building action, potentially appealing to buyers.
Some investors view $CBIO as a "hope and pray" stock, while others see it as a more promising investment opportunity.

Generated by AI

Sentiment

Of the messages about CBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.05% -0.26
Bearish	—	—	0% 0	7.95% +0.26

Bullish· Jun 23

Crescent Biopharma's success may be driving interest in Crescent Biopharma, Inc. (CBIO), with the stock up 32% and $5 in a single day.
CBIO's low float and high percentage gain of 40% may be indicative of a highly volatile and potentially lucrative investment opportunity.
The company's potential for growth, along with that of CAPR, may be driving interest in CBIO, with the stock experiencing significant gains and a relatively low trading volume.

Bearish· Nov 12

The company is discontinuing the development of its lead asset, MarzAA, due to trial recruitment issues.
The company's strategic decision to halt clinical development of MarzAA has led to a decline in the stock price, with the company reporting a loss of $0.80 and a 30% drop in value.
Catalyst Biosciences has been downgraded to Market Perform from Outperform at Raymond James, and also received a lower rating from Jonestrading, citing the company's decision to stop development of its hemophilia drug candidate.

Generated by AI

Topics

Of the messages about CBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	93.51%
Analysts	0%	0%	0%	1.73%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	4.76%

Earnings· Nov 1

Catalyst Biosciences reports Q3 operating and financial results, with a focus on key performance indicators and future prospects.
The company provides an update on its corporate progress, highlighting achievements and challenges.
Catalyst Biosciences releases its Q3 earnings report, offering insights into its financial health and operational performance.

Analysts· Feb 9

Analysts at Ladenburg raised Crescent Biopharma's (CBIO) price target to $47 from $14.
Catalyst Biosciences (CBIO) announced positive top-line data from a Phase 1/2 study of its hemophilia B treatment, CB 2679d/ISU304.
Chardan Capital Markets raised its price target for CBIO to $75, citing the company's promising hemophilia B treatment.

Announcements· Feb 28

Catalyst Biosciences signs agreement with GC Biopharma to sell rare disease pipeline in hematology for $6M.
The net proceeds from the transaction will be distributed to holders of the contingent value right issued to Catalyst stockholders of record on January 5, 2023.
Catalyst stock surges 50% as GC Biopharma acquires 3 blood disorder programs.

Generated by AI

Community

Of the messages about CBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	66.67%	23.93%	13.71%
Newcomers	33.33%	33.33%	76.07%	86.29%

Regulars· Jun 21

$CBIO's 10-day Moving Average crossed above its 50-day Moving Average on May 15, 2023, which could be a bullish signal.
The stock has been trending upward with a 15.6% increase so far, and some regulars are waiting for pullbacks to enter the market.
$CBIO's price has been fluctuating, with a 44% gain since earlier in the day, but some participants are cautious and advise setting stop losses and taking profits where possible.

Newcomers· Feb 19

Crescent Biopharma's stock price surged 21% after the company announced the dosing of the first patient in its ASCEND global phase 1/2 clinical trial for a tumor medication.
The company's stock price also rose after the announcement of acquisition and updated guidance, with Cardinal Infrastructure Group acquiring Cardinal Infrastructure Group, and Crescent Biopharma's stock price increasing by 16%.
The stock price of Crescent Biopharma broke through key resistance levels, with analysts setting a new target price of $15.03, citing inducement awards as a catalyst for the stock's rise.

Generated by AI

News

The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)

4d agoSeeking Alpha

Crescent Biopharma at Morgan Stanley conference: pipeline bets build

15d agoInvesting.com

Crescent Biopharma at Cantor conference: global trial push

19d agoInvesting.com

Crescent Biopharma to Present at September Investor Conferences

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.Morgan Stanley 24th Annual Global He

27d agoca.finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 19,425 shares of the Company’s ordinary shares to one non-executive employee as equity inducement awards under the Cr

1mo agoca.finance.yahoo.com

Also Discussed

Investors talking about CBIO also mention

#	Name	Attention
1	Pulmatrix Inc.PULM	0%0
2	OptimumBank Holdings Inc.OPHC	0%0
3	MRTX - Mirati Therapeutics, Inc.	——
4	Moleculin Biotech, Inc.MBRX	0%0
5	MRNS - Marinus Pharmaceuticals, Inc.	——
6	CBAY - CymaBay Therapeutics, Inc.	——
7	Vericel CorporationVCEL	0%0
8	Bio Green Med Solution, Inc.CYCC	0%new
9	BLPH - Bellerophon Therapeutics, Inc.	——
10	Verastem Inc.VSTM	0%0

Crescent Biopharma Inc.

Healthcare
Biotechnology

Crescent Biopharma Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics for solid tumors. Its current pipeline centers on antibody-based programs, including bispecific antibodies and antibody-drug conjugates designed to address key biological pathways involved in cancer growth and progression. The company’s lead efforts include CR-001, a PD-1 x VEGF bispecific antibody, along with additional candidates aimed at treating advanced solid tumors. Crescent Biopharma Inc. operates in the highly specialized biopharmaceutical sector, where research, clinical development, and strategic collaborations are central to advancing new treatment options. The company’s role in the market is defined by its emphasis on precision-engineered cancer therapies and its focus on late-stage disease areas with significant unmet medical need.

Website

Location

300 Fifth Avenue

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about CBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 30

Crescent Biopharma, Inc. ($CBIO) is a clinical-stage biotech company developing next-gen oncology treatments, including a PD-1/VEGF bispecific.
The company's stock has shown confidence-building action, potentially appealing to buyers.
Some investors view $CBIO as a "hope and pray" stock, while others see it as a more promising investment opportunity.

Generated by AI

Sentiment

Of the messages about CBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.05% -0.26
Bearish	—	—	0% 0	7.95% +0.26

Bullish· Jun 23

Crescent Biopharma's success may be driving interest in Crescent Biopharma, Inc. (CBIO), with the stock up 32% and $5 in a single day.
CBIO's low float and high percentage gain of 40% may be indicative of a highly volatile and potentially lucrative investment opportunity.
The company's potential for growth, along with that of CAPR, may be driving interest in CBIO, with the stock experiencing significant gains and a relatively low trading volume.

Bearish· Nov 12

The company is discontinuing the development of its lead asset, MarzAA, due to trial recruitment issues.
The company's strategic decision to halt clinical development of MarzAA has led to a decline in the stock price, with the company reporting a loss of $0.80 and a 30% drop in value.
Catalyst Biosciences has been downgraded to Market Perform from Outperform at Raymond James, and also received a lower rating from Jonestrading, citing the company's decision to stop development of its hemophilia drug candidate.

Generated by AI

Topics

Of the messages about CBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	93.51%
Analysts	0%	0%	0%	1.73%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	4.76%

Earnings· Nov 1

Catalyst Biosciences reports Q3 operating and financial results, with a focus on key performance indicators and future prospects.
The company provides an update on its corporate progress, highlighting achievements and challenges.
Catalyst Biosciences releases its Q3 earnings report, offering insights into its financial health and operational performance.

Analysts· Feb 9

Analysts at Ladenburg raised Crescent Biopharma's (CBIO) price target to $47 from $14.
Catalyst Biosciences (CBIO) announced positive top-line data from a Phase 1/2 study of its hemophilia B treatment, CB 2679d/ISU304.
Chardan Capital Markets raised its price target for CBIO to $75, citing the company's promising hemophilia B treatment.

Announcements· Feb 28

Catalyst Biosciences signs agreement with GC Biopharma to sell rare disease pipeline in hematology for $6M.
The net proceeds from the transaction will be distributed to holders of the contingent value right issued to Catalyst stockholders of record on January 5, 2023.
Catalyst stock surges 50% as GC Biopharma acquires 3 blood disorder programs.

Generated by AI

Community

Of the messages about CBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	66.67%	23.93%	13.71%
Newcomers	33.33%	33.33%	76.07%	86.29%

Regulars· Jun 21

$CBIO's 10-day Moving Average crossed above its 50-day Moving Average on May 15, 2023, which could be a bullish signal.
The stock has been trending upward with a 15.6% increase so far, and some regulars are waiting for pullbacks to enter the market.
$CBIO's price has been fluctuating, with a 44% gain since earlier in the day, but some participants are cautious and advise setting stop losses and taking profits where possible.

Newcomers· Feb 19

Crescent Biopharma's stock price surged 21% after the company announced the dosing of the first patient in its ASCEND global phase 1/2 clinical trial for a tumor medication.
The company's stock price also rose after the announcement of acquisition and updated guidance, with Cardinal Infrastructure Group acquiring Cardinal Infrastructure Group, and Crescent Biopharma's stock price increasing by 16%.
The stock price of Crescent Biopharma broke through key resistance levels, with analysts setting a new target price of $15.03, citing inducement awards as a catalyst for the stock's rise.

Generated by AI

Crescent Biopharma

Social

Mar 30

Bullish· Jun 23

Bearish· Nov 12

Earnings· Nov 1

Analysts· Feb 9

Announcements· Feb 28

Regulars· Jun 21

Newcomers· Feb 19

The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)

Crescent Biopharma at Morgan Stanley conference: pipeline bets build

Crescent Biopharma at Cantor conference: global trial push

Crescent Biopharma to Present at September Investor Conferences

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Crescent Biopharma Announces Grants of Inducement Awards

Also Discussed

Crescent Biopharma Inc.

Company Information

Location

The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)

Crescent Biopharma at Morgan Stanley conference: pipeline bets build

Crescent Biopharma at Cantor conference: global trial push

Crescent Biopharma to Present at September Investor Conferences

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)

Crescent Biopharma Announces Grants of Inducement Awards

Also Discussed

Social

Mar 30

Bullish· Jun 23

Bearish· Nov 12

Earnings· Nov 1

Analysts· Feb 9

Announcements· Feb 28

Regulars· Jun 21

Newcomers· Feb 19